Diagnosis and treatment progress of chronic myeloid leukemia

Chronic myeloid leukemia (CML) has made a milestone progress due to the development of the first generation tyrosine kinase inhibitor(TKI). Nowadays, most clinical trials in CML focus on discontinuation, even the second discontinuation, and the third generation TKI against T315I mutation. The conventional treatments are more focused on decreasing BCR-ABL transcripts rapidly. At the same time, the treatment management of some special patients has been valued. Key words: Leukemia, myelogenous, chronic, BCR-ABL positive; Drug therapy, combination; Tyrosine kinase inhibitor; Digital polymerase chain reaction; Discontinuation trial